Nurix Therapeutics (NRIX) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed Sarepta Therapeutics (SRPT) over the past year, losing 23.3% versus a loss of 24.6%. Over five years, NRIX leads with a -57.3% price change compared with -83.3% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.43 billion vs $1.40 billion), about 1.0 times the size, while Nurix Therapeutics is growing revenue faster (+54.0% vs +15.6%).
On valuation, Nurix Therapeutics trades at a lower trailing P/E (5.3x vs 666.5x for Sarepta Therapeutics). Sarepta Therapeutics converts more of its revenue into profit, with a net margin of -32.5% versus -314.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | SRPT |
|---|---|---|
| Share price | $12.85 | $13.33 |
| Market cap | $1.40B | $1.43B |
| 1-day change | -5.55% | -5.93% |
| YTD return | -32.26% | -38.06% |
| 1-year return | -23.33% | -24.65% |
| 5-year return | -57.25% | -83.26% |
| P/E ratio (TTM) | 5.29 | 666.50 |
| Forward P/E | — | 8.87 |
| EPS (TTM) | $2.43 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $83.98M | $2.20B |
| Revenue growth (YoY) | +53.95% | +15.58% |
| Net income (latest FY) | $-264.46M | $-713.41M |
| Gross margin | — | 98.84% |
| Operating margin | -340.16% | -31.83% |
| Net margin | -314.90% | -32.45% |
| 52-week high | $28.23 | $24.68 |
| 52-week low | $12.83 | $13.25 |
| Distance from 52-week high | -54.50% | -45.99% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +160.80% | +63.32% |
| Average volume | 2.47M | 2.70M |
| Shares outstanding | 109.25M | 107.24M |
| Employees | 317 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sarepta Therapeutics trades at a higher earnings multiple (666.5x vs 5.3x trailing P/E).
- Sarepta Therapeutics is more profitable, keeping -32.5 cents of every revenue dollar as net income versus -314.9 cents for Nurix Therapeutics.
- Nurix Therapeutics grew revenue faster in its latest fiscal year (+53.95% vs +15.58%).
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
NRIX vs SRPT FAQ
Which is bigger, Nurix Therapeutics or Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.43B compared with $1.40B for Nurix Therapeutics (NRIX).
Which stock has performed better over the past year, NRIX or SRPT?
NRIX returned -23.33% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NRIX or SRPT?
NRIX has the lower trailing P/E at 5.3, versus 666.5 for SRPT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Nurix Therapeutics and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.